Connect with us

Technology

Fliggy Reports Strong Growth as 22 Top Brands Surpass RMB100 Million in Sales During Double 11

Published

on

Platform drives significant rise in transactions and expands user base amid challenging market conditions

HANGZHOU, China, Nov. 12, 2024 /PRNewswire/ — Fliggy, a leading online travel platform and wholly-owned subsidiary of Alibaba Group (NYSE: BABA and HKEX: 9988), has posted strong growth during the 2024 Double 11 shopping event, marking a standout finish to this year’s Global Travel Festival. The platform reported robust double-digit year-on-year sales growth, with a 40% increase in the number of shoppers and 22 brands generating over RMB100 million in gross merchandise value (GMV).

As of midnight on November 12, the GMV for reserved promotional items increased by nearly 90% compared to last year, indicating a faster pace of bookings. Fliggy’s official content-driven sales channels, including its Fliggy Super VIP livestream, performed strongly, with 19 individual products exceeding RMB10 million each.

Zhuoran Zhuang, CEO of Fliggy, said, “Our strong performance during Double 11 underscores our commitment to enhancing the travel experience for consumers and empowering tourism businesses. Despite a challenging market, we’ve delivered robust and high-quality growth. By continuously innovating our systems and marketing tools, we provide greater value to both travelers and partners, reinforcing our role as more than just a traditional online travel agency (OTA). This year’s record-breaking achievement reflects the trust we’ve earned from our clients.”

“Buy Now, Plan Later” drives growth

The “Buy Now, Plan Later” model – where consumers purchase travel products for future use without committing to immediate travel dates or visa arrangements at the time of purchase – emerged as the dominant trend in tourism. This year’s Double 11 event saw a 40% increase in the number of shoppers compared to last year, with new users making up about one-third of the total number of shoppers.

Fliggy reported record-breaking sales across a wide array of travel products. Nearly 1 million flexible “All You Can Fly” tickets and multi-trip flight passes were sold, along with nearly 3 million hotel packages and over 1.1 million amusement park tickets and leisure packages. New offerings, including RV travel passes, car charter tours, Arctic cruises, and hotel stays across 32 global cities, further bolstered the platform’s growth. These products spanned nearly 200 countries and regions, from domestic destinations like Nujiang in Yunnan to Bomi in Tibet, and from Svalbard in Norway to Queenstown in New Zealand.

Outbound travel, in particular, saw strong demand, with Fliggy data revealing that the share of outbound travel products in this mega campaign increased by 30% year-on-year. Popular destinations included Hong Kong SAR, Japan, Macau SAR, Thailand, South Korea, Malaysia, US, Singapore, Vietnam, and Australia. Meanwhile, Iceland, Turkey, Cambodia, Fiji, and France were among the fastest-growing destinations compared to last year.

Fliggy’s success during Double 11 also highlighted the appeal of its “Buy Now, Plan Later” offerings. As of midnight on November 12, the platform reported a nearly 90% year-on-year surge in GMV for reserved promotional products. High demand has been evident across popular theme parks, with Shanghai Disney Resort, Beijing Universal Resort, and Universal Studios Japan all seeing significant increases in reservation rates. Some tour activities have reached booking rates of nearly 50%, while flight passes are also experiencing strong demand. For example, China United Airlines’ seasonal unlimited one-way tickets have seen reservations top 40%. Car rental pass bookings have risen sharply, while hotel packages are seeing a notable uptick, with bookings for ski resorts approaching one-third of total reservations.

A strong season for merchants

Fliggy’s Double 11 event sets a new benchmark for merchant success. This year, a record 22 major brands – 8 more than last year – surpassed RMB100 million in GMV. These included Shanghai Disney Resort, Beijing Universal Resort, Chimelong Tourist Resort, Songtsam, Hong Kong Disneyland, and major hotel groups like Marriott, Wanda Hotels & Resorts, New Century Tourism Group, Hilton, Hyatt, IHG, Banyan Group, Accor, Club Med, Senbo Resort, as well as airlines such as Air China, China Eastern Airlines, China Southern Airlines, Loong Air, Sichuan Airlines, All Nippon Airways (ANA), and Qatar Airways.

Fliggy capitalized on the momentum by offering dynamic pricing products with set purchase and redemption dates, which quickly gained traction. The platform partnered with major brands, including 40 airlines – such as Air China, China Eastern Airlines, China Southern Airlines – and over 6,000 hotel brands, including Marriott, Hilton, Accor, Hyatt, Wanda, and Narada to offer flash sales, with some offering deals starting at RMB1 and additional loyalty points. The strategy proved successful, with Fliggy recording a 120% year-on-year increase in GMV for hotel bookings and an approximately 70% rise in conversion rates.

Double 11 solidifies its role in tourism

For travel businesses, the Double 11 event and the “Buy Now, Plan Later” model have become essential tools for customer acquisition and revenue growth during the off-season. Beyond immediate sales, these initiatives help travel companies manage inventory and generate medium- to long-term customer insights, improving operational decision-making and product offerings.

This year’s Double 11 event has reinforced Fliggy’s position as a key player in the travel industry. With its combination of innovative offerings, a customer-centric approach, and extensive partnerships, Fliggy is poised to continue to lead the way in the global tourism market.

About Fliggy

Fliggy is a wholly-owned subsidiary of Alibaba Group (NYSE: BABA and HKEX: 9988 (HKD Counter) and 89988 (RMB Counter)), and is one of the leading online travel platforms in China. Fliggy places a strong emphasis on innovation in its products and services, catering to the increasingly personalized and diversified needs of consumers in both China and overseas markets.

Leveraging Fliggy’s advantage as part of the Alibaba ecosystem, merchants can benefit from the vast user base within the Group. Fliggy also collaborates with partners through a full-service management format, helping more merchants, especially small and medium-sized ones, easily and efficiently share opportunities enabled by digitalization.

Fliggy’s long-term strategy is to promote the digital transformation of the tourism industry, using an open platform and mechanisms to help the industry make better use of digital business infrastructure for their operations.

Media Contacts

Fliggy
FliggyMedia@alibaba-inc.com

Paradigm Consulting
Rebecca Liu
fliggy@paradigmconsulting.com.hk
+852 6036 5060

View original content:https://www.prnewswire.com/apac/news-releases/fliggy-reports-strong-growth-as-22-top-brands-surpass-rmb100-million-in-sales-during-double-11-302302346.html

SOURCE fliggy

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Marvion Inc. Subsidiary Signs Agreement with Engineering Firm for Construction of New State-of-the-Art Warehouse Facility

Published

on

By

HONG KONG, Nov. 14, 2024 /PRNewswire/ — Marvion Inc. (OTC: MVNC) is pleased to announce that its subsidiary United Warehouse Management Limited has officially signed a quotation agreement with Star Warehouse Engineering Limited for the construction of a new, state-of-the-art warehouse facility. The new warehouse will be strategically located to support the company’s growing logistics and storage operations, underscoring MVNC’s commitment to scaling up its infrastructure to meet the increasing market demand.

The new warehouse will feature two floors, each spanning 18,000 square feet, for a total floor area of 36,000 square feet. This expansion is set to enhance MVNC’s storage capabilities, streamline supply chain efficiency, and optimize logistics operations to better serve its expanding customer base.

Strategic Infrastructure Investment to Drive Long-Term Growth

This significant investment marks a crucial step in MVNC’s long-term strategic plan to solidify its position as a leader in the logistics and storage services sector. The new warehouse will not only bolster the company’s existing storage capacity but also enable the integration of advanced logistics and storage technologies. The facility will be equipped with modern automated systems with artificial intelligence engine to support high-volume inventory management and faster turnaround times, further strengthening MVNC’s competitive advantage in the region.

Commenting on this milestone, Mr. Chan Sze Yu, CEO of Marvion Inc., said:
“This new warehouse is a testament to our commitment to expanding our infrastructure to meet the ever-growing demand in the logistics industry. By investing in this state-of-the-art facility, we are positioning Marvion to better serve our clients and seize emerging opportunities in the market. This project will not only enhance our operational efficiency but also increase our capacity to support strategic partners like FedEx, SF Express, and other key clients.”

Supporting Sustainable Growth in the Asia-Pacific Region

Aligned with MVNC’s sustainability goals, the new facility will incorporate environmentally friendly design elements, such as energy-efficient lighting systems and optimized insulation to reduce energy consumption. These initiatives underscore MVNC’s dedication to promoting sustainable business practices while driving growth.

The construction is scheduled to begin in Q4 2024, with completion expected by the end Q2 2025. The new facility is projected to generate significant operational synergies, contributing to the company’s continued revenue growth and profitability.

About Marvion Inc.

Marvion Inc. (OTC: MVNC) is a leading logistics and warehousing solutions provider based in Hong Kong. The company specializes in offering one-stop transport and storage services to business clients, leveraging advanced digital technologies and efficient inventory management systems.

Company Website: www.unitedksk.com

View original content:https://www.prnewswire.com/news-releases/marvion-inc-subsidiary-signs-agreement-with-engineering-firm-for-construction-of-new-state-of-the-art-warehouse-facility-302305403.html

SOURCE Marvion Inc.

Continue Reading

Technology

American Liver Foundation Hosts the 33rd Annual Irwin M. Arias Symposium

Published

on

By

Virtual and in-person event, Bridging Basic Science and Liver Disease, brings together hundreds of leading biomedical scientists and physicians from across the globe 

FAIRFIELD, N.J., Nov. 14, 2024 /PRNewswire/ — American Liver Foundation is excited to host its 33rd annual Irwin M. Arias Symposium, Bridging Basic Science and Liver Disease, on Wednesday, November 20th from 9AM to 5PM ET. Hundreds of leading biomedical scientists and physicians around the world will come together for this prestigious hybrid, in-person and virtual, one-day event. Each presentation highlights remarkable scientific advances in basic biology and engineering while also providing cutting edge research for a better understanding of liver diseases and the best treatment options available today.

Bridging Basic Science & Liver Disease brings together leading biomedical scientists and physicians from across globe

This informative symposium features 10 unique plenary talks from renowned researchers such as Presidential Medal of Freedom recipient and physician-geneticist Francis S. Collins, MD, PhD, who led the Human Genome Project and discovered the genes causing several genetic diseases. He also served under three Presidents as the Director of the U.S. National Institutes of Health (NIH), the largest supporter of biomedical research in the world. He is currently leading a bold effort to eradicate Hepatitis C throughout the United States. Anne Carpenter, PhD, is the Senior Director of the Imaging Platform and an Institute Scientist at the Broad Institute of MIT and Harvard. She was included on the Top 100 list of AI leaders for her team’s open-source CellProfiler software that is used by thousands of biologists worldwide and their Cell Painting assay that has been adopted throughout the pharma industry to accelerate drug discoveries. There will also be a collection of three-minute ‘MicroTalks’ delivered by trainee scientists.

“This unique one-day annual symposium is a must-attend event for scientists interested in exploring innovative, groundbreaking research conducted in labs and the therapeutic treatments eventually delivered in clinics across the country,” said Lorraine Stiehl, CEO, American Liver Foundation. “Over the past 33 years, research presented at this event has led to many advances in the diagnosis and treatment of virtually all liver diseases in children and adults. Dr. Irwin M. Arias, recognized throughout the world, has devoted his life’s work to advancing liver disease research, treatments and cures and we’re so grateful for his expertise. Liver patients everywhere have benefited from his preeminent work.”

Symposium co-chairs include Sangeeta Bhatia, MD, PhD, John J. and Dorothy Wilson Professor, Electrical Engineering and Computer Science and Institute of Medical Engineering and Science Department at MIT, and Wolfram Goessling, MD, PhD, Chief of Gastroenterology at Massachusetts General Hospital, Director of the Harvard-MIT Health Sciences & Technology at Harvard Medical School and a Professor of Medicine at Harvard Medical School. The overall programming has been designed to honor Dr. Arias’ founding commitment to ‘bridging’ the gap between the academic, industrial, and clinical research communities – even across disciplines.

“The burden of chronic liver diseases affects over 100 million people in the United States alone and is rapidly becoming a public health crisis,” said Dr. Goessling, Chief of Gastroenterology at Massachusetts General Hospital. “Unfortunately, we currently lack effective tools for prevention, diagnosis and treatment for many liver conditions, so it’s vitally important to connect basic science research with the ongoing needs prevalent in many clinics and the Arias Symposium provides this opportunity.”

“Significant gaps remain in the understanding of many liver diseases and the fundamental systems involved in normal and pathological liver function,” said Dr. Bhatia, John J. and Dorothy Wilson Professor at MIT’s Institute of Medical Engineering and Science Department. “This scientific conference bridges basic science and liver disease while also nurturing successful careers in basic and translational liver research. The Arias Symposium allows us all to come together to share our research, encourage new trainees to learn more about liver disease and offers everyone one-day to learn what’s new and engaging in the world of liver research and science.”

The symposium is open to researchers at every stage of their careers, and they are encouraged to share perspectives from their academic, industrial, and clinical research settings. In-person attendees will benefit from a poster session and networking opportunities with plenary speakers and other attendees. Breakfast, lunch, and a networking reception will also be provided to in-person attendees. Registration is free for all trainees (postdocs, fellows, grads, students, undergrads, etc.). Registration is $50 for in-person attendees other than trainees. Virtual attendance is free but does require registration. Register here for this informative event.

This one-day virtual program will include topics such as:  

It’s Time to Eliminate Hepatitis C in the U.S. Francis Collins, MD, PhD – National Institutes of Health (VIRTUAL)Post-Transplant Alloimmune Hepatitis – What do we know and What’s New Udeme Ekong, MD, MPH, FAASLD – Georgetown University Detecting Liver Phenotypes and Toxicity Using Cell Image Data Anne Carpenter, PhD – Broad Institute of MIT and HarvardSpatial Clonal Tracing in Solid Tissues Fernando Camargo, PhD – Massachusetts Institute of TechnologyHolistic Multi-Scale Molecular Imaging of Human Organs Kwanghun Chung, PhD – Boston Children’s HospitalCell Identity Conversion – Liver Regeneration and Cell Therapy Lijian Hui, PhD – Shanghai Institutes for Biological SciencesDeveloping Cirrhosis Therapies: The Three Grand Challenges Quin Wills, MD, PhD – Ochre BioPediatric Liver Tumors: Clinical Context and Opportunities for Collaboration Allison O’Neill, MD – Dana-Farber Cancer InstituteUnderstanding How the Organism Monitors Liver Sufficiency to Properly Time RegenerationKristin Knouse, MD, PhD – Massachusetts Institute of TechnologyCellular and Molecular Drivers of Liver Cancer Response to ImmunotherapyMiriam Merad, MD, PhD – Mount Sinai School of Medicine

For the full agenda, list of speakers, and registration, please visit alfevents.org/ariassymposium.  

In addition to the Arias Symposium, American Liver Foundation offers a research awards program in three categories, Liver Scholar Award, Postdoctoral Research Fellowship Award, and Pilot Research Awards that recently funded eight highly innovative projects into these rare diseases – PSC, AIH and BA. Since 1979, ALF’s research awards program has provided more than $28 million in research funding. Over 850 qualified scientists and physicians have pursued research careers in liver biology, disease and treatment because they received these grants early in their careers. Learn more at liverfoundation.org/research.

About the American Liver Foundation
American Liver Foundation (ALF) is a national community of patients, caregivers and medical professionals dedicated to helping people improve their liver health. Providing guidance and life-saving resources, we are a beacon for the 100 million Americans affected by liver disease. We advocate for patients and families, fund medical research and educate the public about liver wellness and disease prevention. We bring people together through our educational programs and events and create a network of support that lasts a lifetime. ALF is the largest organization focused on all liver diseases and the trusted voice for patients and families living with liver disease. For more information visit www.liverfoundation.org or call: 1 800 GO LIVER (800-465-4837).

Media Contacts:                   
Julie Kimbrough
JKimbrough@liverfoundation.org              
Direct dial: 646-737-9409   
Karla Thomas     
Direct dial: 773.575.9477        

Facebook
X
LinkedIn
YouTube
Instagram

View original content to download multimedia:https://www.prnewswire.com/news-releases/american-liver-foundation-hosts-the-33rd-annual-irwin-m-arias-symposium-302305187.html

SOURCE American Liver Foundation

Continue Reading

Technology

Avantor® Opens New Bridgewater Innovation Center Focused on Solving Life Science’s Biggest Challenges

Published

on

By

RADNOR, Pa., Nov. 14, 2024 /PRNewswire/ — Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced the opening of its new flagship Bridgewater Innovation Center. The state-of-the-art research and development facility, located in Bridgewater, NJ, is part of Avantor’s network of 13 research and innovation centers across the globe.

Avantor’s new Bridgewater Innovation Center spans 60,000 square feet, doubling its previous laboratory and pilot plant capacity. Purpose-designed for collaborative work, the center houses spaces for upstream and downstream process development, dedicated analytical testing labs, and a viral vector laboratory. An expanded pilot plant supports scale-up simulations, enabling rapid customization across the entire bioprocessing workflow.

“Our new Bridgewater Innovation Center is twice the size of our previous facility and adds capacity, talent and capabilities to support the growing demands for monoclonal antibodies, cell and gene therapy and mRNA workflows,” said Michael Stubblefield, President and CEO of Avantor. “Working side-by-side with customers in our network of innovation centers across the globe enables us to power science at every step to deliver life-changing therapies faster, and more cost effectively.”

The Bridgewater Innovation Center allows Avantor to optimize and accelerate biomanufacturing processes at scale; resulting in faster problem solving, streamlined knowledge exchange, and strategic co-innovation. Staffed with Ph.D. scientists, bioengineers, biologists, and process engineers, this center enhances both capacity and expertise to support customers’ needs. The facility also supports Avantor’s sustainability goals, reinforcing the Company’s commitment to environmental responsibility.

For more information about the Bridgewater Innovation Center, visit: https://www.avantorsciences.com/us/en/about/innovation-in-biopharma/avantor-bridgewater-innovation-center

About Avantor
Avantor® is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. We work side-by-side with customers at every step of the scientific journey to enable breakthroughs in medicine, healthcare, and technology. Our portfolio is used in virtually every stage of the most important research, development and production activities at more than 300,000 customer locations in 180 countries. For more information, visit avantorsciences.com and find us on LinkedInX (Twitter) and Facebook.

Global Media Contact
Eric Van Zanten
Head of External Communications
Avantor
610-529-6219
Eric.VanZanten@avantorsciences.com

Investor Relations Contact
Christina Jones
Vice President, Investor Relations
Avantor
805-617-5297
Christina.Jones@avantorsciences.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/avantor-opens-new-bridgewater-innovation-center-focused-on-solving-life-sciences-biggest-challenges-302304526.html

SOURCE Avantor and Financial News

Continue Reading

Trending